Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques
Open Access
- 22 December 2020
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (2)
Abstract
The aim of this work was to design and test a vaccine regimen focusing the immune response on targets associated with infection prevention. We demonstrated that priming with a DNA vaccine expressing only the HIV Env V1V2 region induces Ab responses targeting the critical region in V2 associated with protection. This work shows that V1V2 scaffold DNA priming immunization provides a method to focus immune responses to the desired target region, in the absence of immune interference by other epitopes. This induced immune responses with improved recognition of epitopes important for protective immunity, namely, V2-specific humoral immune responses inversely correlating with HIV risk of infection in the RV144 trial.Keywords
Funding Information
- HHS | NIH | National Cancer Institute (Intramural funding)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN 272201800004C)
- Henry M. Jackson Foundation (W81XWH-18-2-0040)
This publication has 102 references indexed in Scilit:
- DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challengeProceedings of the National Academy of Sciences, 2013
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Nature, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responsesVaccine, 2012
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responsesCytometry Part A, 2011
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesJournal of Immunological Methods, 2011
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1Molecular Immunology, 2009